Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts


23 Nov 2019


Poster display session


Tumour Site

Breast Cancer


Manickam Paulpandi


Annals of Oncology (2019) 30 (suppl_9): ix1-ix8. 10.1093/annonc/mdz416


M. Paulpandi, K. Murugan

Author affiliations

  • Zoology, Bharathiar University, 641046 - Coimbatore/IN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 19P


Polo-like kinase 1 (PLK1) is a protein kinase plays an important role in the initiation, maintenance, and completion of mitotic process. Human PLK1 has been shown to be over-expressed in a variety of human cancers, and elevated levels of PLK1 have been associated with poor prediction, leading to an attractive target for anticancer therapy.


A novel Silymarin functionalized FeO quantum cores (SiFeO QDs) were synthesized through one step synthesis method. For in vitro assay MTT, apoptotic staining assays and cell cycle analysis were performed. In vivo studies, xenocraft mice further administration of the SiFeO QDs at a dose of 25mg/kg body weight every other day for 14d. after 24h of the last treatment dose, the mice were left to monitor their survival or sacrificed to assess the antitumor activity.


SiFeO QDs inhibited proliferation of Triple negative breast cancer cell lines, with mean inhibitory concentration of (IC50) value about 4.5µg/ml, meanwhile in non-dividing normal cells, it didn’t exhibit any adverse effects upto 50µg/ml. In animal models, administration of SiFeO QDs significantly inhibited the growth of MM2 breast cancer xenografts. It also accompanied by decreased expression of anti-apoptotic proteins, BCL-2, and MCL-1 and increased expression of BAX. Moreover, caspase-3 was activated to a greater extent after SiFeO QDs treatment. Impressively the treated group animal exihibit there is no aberrant effect in vital organs and blood parameters. Tumor growth was significantly inhibited after i.v. injection of SiFeO QDs at dose of 5mg/kg compared to free FeO QDs at dose of 25mg/kg. However, this system remarkably suppressed tumor growth in human breast cancer xenografts.


The significant antitumor efficacy of SiFeO QDs were attributed to the ability of the cores to show both prolonged blood circulation and high accumulation in tumors, as confirmed by near infrared (NIR) imaging systems. Taken all together, the SiFeO QDs hold great potential in biomedical applications especially cancer theranostics due to their versatile nature in therapy as well in diagnostics in clinical tumor biology.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Manickam Paulpandi.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.